___

• [1] Morgan G, Vornanen M, Puitinen J, et al. Changing trends in the incidence of non-Hodgkin’s lymphoma in Europe. Biomed Study Group. Ann Oncol 1997;8 Suppl 2:49-54.
• [2] Moller MB, Pedersen NT, Christensen BE. Diffuse large B-cell lymphoma: clinical implications of extranodal versus nodal presentation—a population-based study of 1575 cases. Br J Haematol 2004;124:151-9.
• [3] Takahashi H, Tomita N, Yokoyama M, et al. Prognostic impact of extranodal involvement in diffuse large B-cell lymphoma in the rituximab era. Cancer 2012;118:4166-72. doi:10.1002/ cncr.27381
• [4] Villa D, Connors JM, Sehn LH, Gascoyne RD, Savage KJ. Diffuse large B-cell lymphoma with involvement of the kidney: outcome and risk of central nervous system relapse. Haematologica 2011;96:1002-7. doi:10.3324/ haematol.2011.041277
• [5] Lopez-Guillermo A, Colomo L, Jimenez M, et al. Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin. J Clin Oncol 2005;23:2797-804. doi:10.1200/JCO.2005.07.155
• [6] Lehners N, Kramer I, Schwarzbich MA, Ho AD, Witzens- Harig M. Analysis of clinical characteristics and outcome of patients with previously untreated diffuse large B-cell lymphoma and renal involvement in the rituximab era. Leuk7869
• [7] Tai WM, Chung J, Tang PL, et al. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre-and post-rituximab. Ann Hematol 2011;90:809-18. doi:10.1007/s00277.010.1150-7
• [8] Fletcher CD, Kahl BS. Central nervous system involvement in diffuse large B-cell lymphoma: an analysis of risks and prevention strategies in the post-rituximab era. Leuk Lymphoma 2014;55:2228-40. doi:10.3109/10428.194.2013.86 9326
• [9] Villa D, Connors JM, Shenkier TN, Gascoyne RD, Sehn LH, Savage KJ. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. Ann Oncol 2010;21:1046-52. doi:10.1093/annonc/mdp432
• [10] Schmitz N, Zeynalova S, Glass B, et al. CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group. Ann Oncol 2012;23:1267-73. doi:10.1093/annonc/ mdr440
• [11] Tomita N, Takasaki H, Ishiyama Y, et al. Intrathecal methotrexate prophylaxis and central nervous system relapse in patients with diffuse large B-cell lymphoma following rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone. Leuk Lymphoma 2015;56:725-9. doi:10.310 9/10428.194.2014.931953
• [12] Ferreri AJ, Bruno-Ventre M, Donadoni G, et al. Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era. Br J Haematol 2015;168:654-62. doi:10.1111/bjh.13194
• [13] Cheah CY, Seymour JF. Central nervous system prophylaxis in non-Hodgkin lymphoma: who, what, and when? Curr Oncol Rep 2015;17:25. doi:10.1007/s11912.015.0450-4
• [14] Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008;9:105-16. doi:10.1016/S1470-2045(08)70002-0
• [15] Pfreundschuh M, Trumper L, Osterborg A, et al. CHOPlike chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379-91. doi:10.1016/S1470-2045(06)70664-7
• [16] Delarue R, Tilly H, Mounier N, et al. Dose-dense rituximab- CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. Lancet Oncol 2013;14:525- 33. doi:10.1016/S1470-2045(13)70122-0
• [17] Pfreundschuh M, Poeschel V, Zeynalova S, et al. Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non- Hodgkin lymphoma study group. J Clin Oncol 2014;32:4127- 33. doi:10.1200/JCO.2013.54.6861
• [18] Ziepert M, Hasenclever D, Kuhnt E, et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol 2010;28:2373- 80. doi:10.1200/JCO.2009.26.2493
• [19] Canet E, Zafrani L, Lambert J, et al. Acute kidney injury in patients with newly diagnosed high-grade hematological malignancies: impact on remission and survival. PLoS One 2013;8:e55870. doi:10.1371/journal.pone.0055870
• [20] Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood 2010;116:2040-5. doi:10.1182/blood-2010-03-276246
• [21] Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 2005;23:4117-26. doi:10.1200/JCO.2005.09.131
• [22] Pfreundschuh M, Kuhnt E, Trumper L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomized study of the MabThera International Trial (MInT) Group. Lancet Oncol 2011;12:1013- 22. doi:10.1016/S1470-2045(11)70235-2
• [23] Habermann TM, Weller EA, Morrison VA, et al. Rituximab- CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24:3121-7. doi:10.1200/JCO.2005.05.1003.
• [24] Howlett C, Snedecor SJ, Landsburg DJ, et al. Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and metaanalysis. Br J Haematol 2015;170:504-14. doi:10.1111/ bjh.13463
• [25] Dunleavy K, Pittaluga S, Maeda LS, et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med 2013;368:1408-16. doi:10.1056/ NEJMoa1214561
• [26] Hanna F, Prakash A, Allan E, Khalafallah AA. Successful treatment of concomitant metastatic prostate cancer and B-cell non-Hodgkin’s lymphoma with R-EPOCH chemotherapy regimen and antiandrogen therapy. BMJ Case Rep 2018;2018. doi:10.1136/bcr-2017-223637
• [27] Kaur A, Abughanimeh O, Zafar Y, Pluard T. Diffuse large B-cell lymphoma presenting as bilateral renal masses: Successful treatment with dose-adjusted REPOCH (Rituximab, Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin) chemotherapy regimen. Cureus 2019;11:e3814. doi:10.7759/cureus.3814